Crescent Biopharma, Inc.

Healthcare · Biotechnology

14.10$ +4.7% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Crescent Biopharma, Inc. (CBIO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 183 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CBIO
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	48	42	37	122	116	129	247	236	225	215	204	192	180	168	162	158	150	143	138	124	108	94	81	65	56	52	69	62	53	45	34	24	16	11	6.0	157	138	240	199	183
Current Assets	47	41	35	120	114	127	246	233	222	212	198	186	175	163	157	153	146	138	134	120	104	91	77	61	54	51	68	60	52	44	33	24	16	11	6.0	154	135	237	196	179
Cash	45	40	35	119	113	124	243	229	220	210	196	184	171	158	155	150	143	137	132	119	102	90	77	60	52	48	65	58	49	42	31	22	14	11	5.6	153	133	213	189	172
Cash & Short-Term Investments	45	40	35	119	113	124	243	229	220	210	196	184	171	158	155	150	143	137	132	119	102	90	77	60	52	48	65	58	49	42	31	22	14	11	5.6	153	133	213	189	172
Receivables	0.6	0.3	0.0	0.1	0.1	0.1	0.2	0.3	0.3	0.4	0.4	0.3	0.6	0.2	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	–	–	–	18	0.0	0.0
Inventory	–	0.2	–	–	–	–	–	–	–	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	4.8	–	4.6	–
Total Liabilities	6.3	7.1	5.3	6.2	7.3	8.9	9.4	7.7	7.1	9.4	12	14	13	14	14	13	12	15	13	12	11	13	13	9.3	7.8	8.9	6.7	7.0	6.7	6.9	5.3	4.4	4.3	5.8	2.6	18	22	37	15	20
Current Liabilities	5.4	6.3	4.5	5.4	6.5	8.2	8.7	7.0	6.4	8.8	8.3	11	10	11	11	9.7	9.8	12	11	10	9.7	12	13	8.9	7.7	8.9	6.7	6.6	6.4	6.8	5.3	4.4	4.3	5.8	2.6	17	20	36	14	19
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	0.7	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.1	0.9	0.7	0.8	0.7	0.7	0.6	0.4	0.3	0.1	–	0.2	0.4	0.4	0.5	0.5
Accounts Payable	1.2	1.6	0.5	0.6	1.6	2.6	3.9	3.2	0.7	2.7	1.9	3.0	1.4	1.4	3.1	1.4	1.1	2.1	2.1	1.2	1.4	2.1	2.3	1.3	0.9	1.0	0.5	0.2	0.3	0.9	0.8	1.0	1.0	1.4	0.1	1.6	2.6	10.0	1.2	2.5
Shareholders' Equity	42	35	32	115	109	120	238	228	218	205	193	179	167	154	148	146	138	128	125	112	97	82	68	56	48	43	62	55	47	38	29	20	11	5.3	3.4	139	117	203	184	163
Retained Earnings	-111	-119	-127	-135	-143	-152	-164	-175	-187	-201	-215	-230	-244	-258	-266	-280	-294	-309	-324	-338	-355	-373	-388	-401	-409	-420	-430	-438	-447	-456	-467	-477	-487	-494	-497	-55	-79	-172	-195	-220
Shares Outstanding	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.8	3.9	17	20	30	31

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings